Mediaboss Marketing

New York, June 16, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Snoring Control Devices Market 2021-2025" - https://www.reportlinker.com/p04796694/?utm_source=GNW Our report on snoring control devices market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the low cost of nasal devices and chin straps, high prevalence of sleep disorders, increasing demand for home-care settings, and increased incidence of chronic diseases and rise in geriatric population. In addition, low cost of nasal devices and chin straps is anticipated to boost the growth of the market as well.The snoring control devices market analysis includes product type segment and geographic landscape.

The snoring control devices market is segmented as below:By Product Type Mandibular advancement devices Tongue stabilizing devices Nasal devices Chin straps Others

By Geographical Landscape North America Europe Asia Rest of World (ROW)

This study identifies the use of 3D printing technology in the production of snoring control devices as one of the prime reasons driving the snoring control devices market growth during the next few years. Also, growing focus toward online promotional and marketing strategies and integration of mobile devices with home healthcare systems will lead to sizable demand in the market.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on snoring control devices market covers the following areas: Snoring control devices market sizing Snoring control devices market forecast Snoring control devices market industry analysis

This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading snoring control devices market vendors that include Apnea Sciences Corp., Fisher and Paykel Healthcare Corp. Ltd., GlaxoSmithKline Plc, Koninklijke Philips NV, Meditas Ltd., Mitsui Chemicals Inc., MPowrx Health and Wellness Products 2012 Inc., ResMed Inc., SomnoMed Ltd., and Tomed GmbH. Also, the snoring control devices market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavios market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.Read the full report: https://www.reportlinker.com/p04796694/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Continued here:
The Global Snoring Control Devices Market is expected to grow by $ 323.25 million during 2021-2025 - GlobeNewswire

BRUSSELS, June 18 (Reuters) - Alphabet (GOOGL.O) unit Google could face its biggest regulatory threat, with EU antitrust regulators set to open a formal investigation into its lucrative digital advertising business before the end of the year, said people familiar with the matter.

It would mark a new front by the EU competition enforcer against Google. It has in the last decade fined the company more than 8 billion euros ($9.8 billion) for blocking rivals in online shopping, Android smartphones and online advertising.

An EU probe would focus on Google's position vis-a-vis advertisers, publishers, intermediaries and rivals, one of the people said, indicating deeper scrutiny than the French antitrust agency's case concluded last week.

Google made $147 billion in revenue from online ads last year, more than any other company in the world. Ads on its properties, including search, YouTube and Gmail, accounted for the bulk of sales and profits.

About 16% of revenue came from its display or network business, in which other media companies use Google technology to sell ads on their website and apps.

Both units are under fire. The U.S. Justice Department, joined by some states, sued Google last year for abusing its dominance in search ads. A group of states led by Texas in a later lawsuit focused on anti-competitive behaviour on the network side of the house.

France last week settled with Google for $268 million and various commitments over similar allegations related to the network business, and the unit also must work closely with Britains competition regulator on upcoming software changes as part of a settlement reached days later.

A sign is seen at the entrance to the Google retail store in the Chelsea neighborhood of New York City, U.S., June 17, 2021. REUTERS/Shannon Stapleton

Read More

The Commission declined to comment. Google did not immediately respond to a request for comment.

A new EU inquiry could end up targeting all of Google's ad empire. Market researcher eMarketer expects Google to control 27% of global online ad spending this year, including 57% for search ads and 10% of display.

While the numbers may not look monopolistic at first blush, advertisers and rivals contend that Google's various software play a role in so many facets of the market that the company is impossible to avoid.

They say Google takes advantage of the dependence buyers, sellers and intermediaries have on it to extract high fees from all sides and block rivals from fairly competing with it.

In a questionnaire sent to Google rivals and third parties earlier this year and seen by Reuters, the EU watchdog asked if advertisers receive rebates when they use Google intermediaries which allow advertisers or media agencies to buy advertising inventory from many sources.

The Commission should conclude ongoing cases before starting new ones, said Thomas Hoppner, a partner at law firm Hausfeld, and who advises several complainants against Google.

"From the practitioner's point of view and from the industry's point of view, it appears equally important to bring investigations into local search and Google's job search to an end when other authorities have opened investigations into Google's adtech," he said.

($1 = 0.8399 euros)

Reporting by Foo Yun Chee; editing by David Evans

Our Standards: The Thomson Reuters Trust Principles.

See original here:
EXCLUSIVE Google's adtech business set to face formal EU probe by year-end -sources - Reuters

LONDON, June 18, 2021 (GLOBE NEWSWIRE) -- Recently,Axion Trade, the world's leading brokerage for financial institutions, expands its operations into APAC, seeking out multiple partnerships with the fastest growing trading education companies in Asia. DeltalyteFX, Axion Trade's newest introducing broker, is one of the key partners who are determined to give new traders an edge in honing their craft.

In 2020, due to the global pandemic situation brought about by COVID-19, trading brokerages have seen a rise of nearly 50% in the number of new accounts being opened and over a 200% rise in assets under management (AUM). In the same year, the average retail trader has lost more than 70% of their trading capital. This brings us to the question: how can one keep up and stay in control with an industry that is ever-changing? The Blueprint; a refined approach based off the strategy of Smart Money Concept, developed by DeltalyteFX, Singapore-based trading education firm could be the answer.

"We're excited going on this journey with Axion Trade. My partner and I have been in the Forex Industry for about close to 4 years. We began with nothing, reinforcing fundamentals such as seeking a deep understanding of Basic Price Actions. It was then when we ventured further into Smart Money Concept, where we then decide that this will be the main strategy in which we would stick to and branch out further from there," said Budi Hidayat, co-founder of DeltalyteFX.

"At DeltalyteFX, we sculpt individuals to design a masterpiece with the understanding of the markets. We feel our that Smart Money Concept is the true way a trader should view the market as it allows us to seek out areas that causes 95% of traders in the world to lose their money. This will then give us an advantage in the market unlike any other," added Sciran Vikneswaran, co-founder of DeltalyteFX.

"It is our honor to be working with such brilliant minds. Their remarkable skills and passion will be greatly beneficial for both new and experienced traders. We look forward achieving great results in this region and establishing a stronghold in APAC," said Amos Tsai Wang, Manging Director of Axion Trade.

For additional information on how to join DeltalyteFX's mentorship course, drop a message at their following social media platforms:

DeltalyteFX's Facebook

DeltalyteFX's Instagram

DeltalyteFX's Telegram

About Axion Trade

Axion Trade is a US-based leading currency solutions provider that provides retail and institutional clients competitive spreads and superior liquidity.Axion Trade holds a Money Services Business (MSB) License issued by USA, Registration No. 31000175281855 for foreign exchange dealing, and is registered with the Commodity Futures Trading Commission and National Futures Association under NFA ID 0533447. With a proven track record of strong financial results and stable growth, Axion Trade has put itself in an enviable position as a trusted market leader and innovator.

For additional information, please send an email to enquiry@axiontrade.net.

Media ContactCompany: Axion TradeContact: Oliver ElmhirstTelephone: +44 800 060 8702Email: Oliver.Elmhirst@axiontrade.netWebsite: https://axiontrade.net/

SOURCE: Axion Trade

Original post:
Axion Trade and DeltalyteFX: Unlocking the Secrets to High - GlobeNewswire

June 16 (Reuters) - One in three U.S. election officials feels unsafe on the job and one in six reported being threatened because of their work, according to a survey published Wednesday by New York Universitys nonpartisan Brennan Center for Justice.

The results reflect a reckoning in the wake of election in which the loser, former Republican President Donald Trump, spent months falsely alleging the contest was "rigged" against him. Those claims sparked threats and actual violence, such as the deadly U.S. Capitol riots on Jan. 6.

A Reuters investigation published on Friday found that election workers and their families continue to face threats and intimidation months after Trump's loss in November to Democrat Joe Biden. The intimidation has been particularly severe in Georgia, where Secretary of State Brad Raffensperger and other Republican election officials refuted Trump's stolen-election claims.

Election officials' fears for their safety portend major staffing problems in future votes, the Brennan Center said.

Large numbers of election officials have resigned in the past year, raising alarm bells. But the wave of departures could soon turn into a tsunami, said a report produced jointly by the Brennan Center and the Bipartisan Policy Center, a centrist Washington think tank.

The Brennan Center surveyed 233 local election officials across the country between April 1 and 7. The survey had a 6.4% margin of error, the center said.

Many election workers who were surveyed blamed social media for spreading falsehoods. About 54% of election officials said social media made their work more dangerous and 78% said it made it more difficult. Those findings reflect a dangerous rise in disinformation, the report from the two research organizations said.

Trump's false claims that voter fraud cost him the election spread quickly among supporters over social media platforms such as Facebook and Twitter and other online forums.

"This disinformation has indelibly changed the lives and careers of election officials," the report said, calling on technology and media companies to help slow the spread of disinformation.

The two research centers urged the Department of Justice to create "an election threats task force" to work with federal, state, and local law enforcement to investigate threats against officials and poll workers. The report urged states to protect election employees' personal information and pay for security measures such as home intrusion detection systems.

U.S. Attorney General Merrick Garland acknowledged the rising threat to election workers in a speech on Friday. Garland, a Biden appointee, said his Justice Department will aggressively protect voting rights at a time when many Republican-led states are tightening election laws.

"We have not been blind to the dramatic increase in menacing and violent threats against all manner of state and local election workers, ranging from the highest administrators to volunteer poll workers," he said. "Such threats undermine our electoral process and violate a myriad of federal laws."

U.S. elections are run by two kinds of workers - permanent staffers employed by officials such as secretaries of state, and large numbers of temporary workers brought in to manage polling places on election days. Those temporary workers are vital to the process - guiding voters, answering questions, verifying IDs - and they work long hours for low pay.

Even before November's contested election, counties and local governments struggled to fill these roles. The federal U.S. Election Assistance Commission found that in the 2016 presidential vote, 65% of jurisdictions nationwide reported that it was very difficult or somewhat difficult to recruit enough poll workers.

The Brennan Center report said that as of last year, almost 35% of local election officials were eligible to retire by the 2024 presidential election.

It is not clear who will replace them, nor whether those willing to take the job in the future will share the commitment to free and fair elections that was so critical in 2020, the report said.

Reporting by Jason Szep. Editing by Brian Thevenot

Our Standards: The Thomson Reuters Trust Principles.

Go here to read the rest:
One in three U.S. election officials feels unsafe - survey - Reuters

NEW YORK, June 18, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc.(NASDAQ: TGTX),today announcedthe presentation of data from the ULTIMATE I & II global, active controlled, Phase 3 trials evaluatingublituximab, the Companys investigational novel, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide,in patients with relapsing forms of multiple sclerosis (RMS), during the 7th Congress of the European Academy of Neurology (EAN).This data was previously presented at the American Academy of Neurology (AAN) 73rd Annual Meeting.

Oral Presentation Title: Ublituximab versus teriflunomide in relapsing multiple sclerosis (RMS): Results of the Phase 3 ULTIMATE I and II trials

The ULTIMATE I & II studies investigated the safety and efficacy of a one-hour 450mg infusion of ublituximab every six months, following the Day 1 infusion (150mg over four hours). The studies were conducted under Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). Additionally, data from these studies are intended to support a Biologics License Application (BLA) submission for ublituximab in RMS targeted in the third quarter of 2021.

Data highlights from the ULTIMATE I & II Phase 3 studies in patients with RMS include:

Primary Endpoint: Annualized Relapse Rate (ARR) Results

MRI Results

No Evidence of Disease Activity (NEDA) Results

Prespecified Pooled Disability Results

Ublituximab was generally well tolerated with no unexpected safety signals. Overall, the proportion of patients in the ublituximab group with adverse events was similar to the teriflunomide group in a pooled analysis of both studies (approximately 88% in each treatment group); the most common adverse event associated with ublituximab was infusion related reactions (47.7% of patients who received ublituximab experienced at least one infusion-related reaction vs. 12.2 percent for the teriflunomide group).

ABOUT THE ULTIMATE I & II TRIALSULTIMATE I and ULTIMATE II are two independent Phase 3, randomized, double-blinded, active-controlled, global, multi-center studies evaluating the efficacy and safety/tolerability of ublituximab (450mg dose administered by one-hour intravenous infusion every 6 months, following a Day 1 infusion of 150mg over four hours and a Day 15 infusion of 450mg over one hour) versus teriflunomide (14mg oral tablets taken once daily) in subjects with relapsing forms of Multiple Sclerosis (RMS). The ULTIMATE I & II trials enrolled a total of 1,094 patients with RMS across 10 countries. These trials were led by Lawrence Steinman, MD, Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics at Stanford University and were conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). Both studies have met their primary endpoint with ublituximab treatment demonstrating a statistically significant reduction in annualized relapse rate (ARR) over a 96-week period (p<0.005 in each trial). Ublituximab treatment resulted in an ARR of <0.10 in each of ULTIMATE I & II, with a relative reduction in ARR of approximately 60% and 50%, respectively, over teriflunomide. Key secondary MRI endpoints have also been met. Data from these studies are intended to support a Biologics License Application (BLA) submission for ublituximab in RMS targeted Q3 2021. Additional information on these clinical trials can be found at http://www.clinicaltrials.gov (NCT03277261; NCT03277248).

ABOUT UBLITUXIMAB Ublituximab is an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. When ublituximab binds to the B-cell it triggers a series of immunological reactions, including antibody-dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC), leading to destruction of the cell. Additionally, ublituximab is uniquely designed, to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, has been shown to enhance the potency of ublituximab, especially the ADCC activity. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of B-cell malignancies and autoimmune disorders, both diseases driven by the abnormal growth or function of B-cells.

ABOUT MULTIPLE SCLEROSIS Relapsing multiple sclerosis (RMS) is a chronic demyelinating disease of the central nervous system (CNS) and includes people with relapsing-remitting multiple sclerosis (RRMS) and people with secondary progressive multiple sclerosis (SPMS) who continue to experience relapses. RRMS is the most common form of multiple sclerosis (MS) and is characterized by episodes of new or worsening signs or symptoms (relapses) followed by periods of recovery. It is estimated that nearly 1 million people are living with MS in the United States and approximately 85% are initially diagnosed with RRMS.1,2The majority of people who are diagnosed with RRMS will eventually transition to SPMS, in which they experience steadily worsening disability over time. Worldwide, more than 2.3 million people have a diagnosis of MS.1

ABOUT TG THERAPEUTICS, INC.TG Therapeuticsis a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from theU.S.FDA for UKONIQ(umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has two programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development.For more information, visitwww.tgtherapeutics.com, and follow us on Twitter@TGTherapeuticsandLinkedin.

UKONIQ is a trademark ofTG Therapeutics, Inc.

Cautionary StatementThis press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Such forward looking statements include but are not limited to statements regarding the results of the ULTIMATE I & II studies and the Companys plans and timelines for submission of a Biologics License Application (BLA) for ublituximab for the treatment of relapsing forms of Multiple Sclerosis (RMS).

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. In addition to the risk factors identified from time to time in our reports filed with theU.S. Securities and Exchange Commission (SEC), factors that could cause our actual results to differ materially include the following: the risk that the data from the ULTIMATE I & II trials that we announce or publish may change, or the perceived product profile may be impacted, as more data or additional endpoints (including efficacy and safety) are analyzed; the risk that safety issues will emerge despite our belief that there were no unexpected safety signals identified in the ULTIMATE I & II trials ; our ability to complete the BLA submission for ublituximab in RMS within the timeline projected and the risk that FDA will not accept the submission; the risk that the clinical results from the ULTIMATE I & II trials will not support regulatory approval of ublituximab to treat RMS for efficacy, safety or other issues or, if approved, that we will not receive regulatory approval within the timeline projected; the risk that if approved, ublituximab will not be commercially successful; our ability to expand our commercial infrastructure, and successfully launch, market and sell ublituximab in RMS if approved; the Companys reliance on third parties for manufacturing, distribution and supply, and a range of other support functions for our commercial and clinical products, including ublituximab; the uncertainties inherent in research and development; and the risk that the ongoing COVID-19 pandemic and associated government control measures have an adverse impact on our research and development plans or commercialization efforts. Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year endedDecember 31, 2020and in our other filings with theSEC. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

_________________________________________________________

1.MS Prevalence. National Multiple Sclerosis Society website.https://www.nationalmssociety.org/About-the-Society/MS-Prevalence. Accessed October 26, 2020.2.Multiple Sclerosis International Federation, 2013 via Datamonitor p. 236.

Read the original post:
TG Therapeutics Announces Presentation of Data from the - GlobeNewswire